Alzheimer’s Prevention and Preventive Neurology: Trust but Verify

A 42-year-old woman, experiencing brain fog, was scrolling on her phone when a clip on Instagram about an Alzheimer’s blood test stopped her in her tracks. She saw her grandmother suffer from dementia and wondered if it might explain her symptoms. 

Her primary care doctor ordered an amyloid blood test, which came back “positive.” A PET scan was quickly arranged, turning to a frightening question: “Do I have Alzheimer’s disease, doctor?” This led her to seek out the help of our preventive neurology team.

She was otherwise healthy and lacked the clinical characteristics consistent with an Alzheimer’s diagnosis. We repeated the amyloid test—running it in duplicates for greater accuracy, along with our usual more comprehensive blood panel—and approached interpretation with disciplined clinical rigor. The original "positive" result was not a diagnosis, but a false positive that required verification, context, and restraint in interpretation.

Unfortunately, this is not an isolated case. It exemplifies risks when public discourse moves faster than clinical practice, leading to emerging biomarker interpretation as definitive conclusions rather than probabilistic signals. Testing has become easier to order, more visible in media, and more widely available outside specialty settings. However, the clinical infrastructure and trained personnel required to interpret those results responsibly have not kept pace.

Trust in medical practice is increasingly a limited resource. Scientific progress is outpacing public understanding, while marketing and media often move faster than validation, creating a false sense of certainty from what is still uncertain. Therefore, we must manage trust while developing systems that keep innovation grounded in reality.

Innovation should move quickly, but verification must keep pace.

Entrepreneurship optimizes for speed, scale, and adoption, while clinical medicine optimizes for safety, reliability, and patient-centered outcomes. The temptation in any fast-moving field is to move fast (and “break things”) and assume that widespread adoption will reveal what works. In brain health, that instinct collides with a hard constraint: The cost of being wrong (i.e., a false positive) is borne immediately by patients, triggering unnecessary testing, psychological distress, and misguided clinical decisions long before evidence has time to self-correct in the public narrative.

Leadership in medical innovation requires increasing “evidence velocity” without compromising validity, transparency, or patient welfare. Innovation should move quickly, but verification must keep pace.

Blood biomarkers for Alzheimer’s and related neurodegenerative disorders are among the most promising advancements in neurology. They enable minimally invasive, repeatable testing that could enable earlier detection, long-term monitoring, and more accurate assessment of treatment responses (similar to a “cholesterol test for the brain”).

However, the correct posture today is cautious optimism. Clinically, this means treating biomarkers as signals, not verdicts. It means repeating tests when appropriate rather than anchoring on a single draw. It means attention to pre-analytic variables from sample collection to processing, from shipping and storage to temperature excursions. It means assay literacy, calibrator shifts, and the gap that can exist between a published research assay and the commercially deployed test. It also means acknowledging and having agency for high-stakes decisions and monitoring reliability.

Our patient example illustrates the human cost of skipping these steps. A single “positive” result triggered a cascade, not scientific, but psychological, administrative, and commercial. Verification, clinical rigor, and a commitment to scientific quality halted that cascade, protecting the patient from an avoidable diagnostic spiral.

The clinical standard must shift from late-stage Alzheimer’s diagnosis to earlier risk assessment and management guided by biology and clinical context. Cardiology is the closest precedent. Twenty to thirty years ago, cardiovascular prevention was also in its “early biomarker” era. The field moved beyond measuring “total cholesterol” alone to include lipoprotein fractions, imaging, risk-stratification tools, and longitudinal monitoring. It built norms that improved decisions without claiming perfect prediction. 

Brain health needs similar maturation. Not one biomarker or headline, but a structured approach explicit about uncertainty and rigorous about confirmation.

Making that shift requires more than better tests. It requires infrastructure that can translate discovery into dependable clinical practice. Our research at the Institute for Neurodegenerative Diseases focuses on building the bridge from bench to bedside to standard of care while raising the standard for accuracy and actionability. We have separately developed new blood panels and digital engagement tools to democratize access to preventive neurology and brain health education for free via the National Institutes of Health-funded RetainYourBrain platform, launching at-home testing and guidance soon. 

Frontline care teams must understand the capabilities and limitations of testing so people at risk receive rigorous, evidence-based care rather than panic and misinformation. Implementing preventive neurology at scale requires honest conversations and ethical guardrails that consistently prioritize people over profits. By achieving this successfully, preventive neurology will transition from an aspiration to an accepted standard of care.